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The feasibility of giving i.v. or hepatic arterial
infusion of high dose Mitomycin C (HDMMC)
followed by autologous bone marrow transplant was
studied in 4 patients with metastatic tumour in
the liver. Doses ranged from 40-50 mg m-2. The
dose limiting toxicity of Mitomycin C is
myelosuppression. High dose Mitomycin C has
been given i.v. followed by autologous bone
marrow transplantation with complete
haematological recovery (Champlin, 1980;
DiStefano, 1980; Sarna, 1980). Autologous bone
marrow transplant accelerates haematological
recovery (DiStefano, 1980). Non-haematological
toxicity has been nausea, vomiting, diarrhoea,
hepatotoxicity (veno-occlusive pathology),
haemorrhagic pancreatitis, pleuropericarditis, severe
stomatitis, and severe haemorrhagic enterocolitis
with doses of 20-40mgm-2day-1 x 3 days
(DiStefano, 1980). Intra-arterial infusion of
chemotherapy has two theoretical advantages over
i.v. infusion: achievement of a higher drug
concentration in the tumour bearing region and
potential for a substantial uptake of the drug by
the tumour in its first passage which might reduce
excessive peripheral toxicity (Chen, 1980). A clinical
pharmacological study with Mitomycin C confirms
these theoretical advantages (Hashimoto, 1978).
Intra-arterial infusion of Mitomycin C in
conventional dosage has been used to treat
bronchial and hepatic tumours (Hellekant, 1978;
Patt, 1981).
All patients gave written informed consent to the
procedure. The first patient had high dose
Mitomycin C (HDMMC) i.v., the second had half
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the dose i.v. and half by hepatic arterial infusion
simultaneously. The third and fourth had HDMMC
by hepatic arterial infusion alone. Two patients had
breast adenocarcinoma metastatic to liver and
bone, refractory to therapy, one had rectal
adenocarcinoma metastatic to liver and one had
cholangiocarcinoma extensively invading the liver.
The first two patients had been extensively
pretreated and the second two were previously
untreated. The mean age was 33 years (24-40) and
their performance status ranged from 20-100%
(Karnofsky Performance Status), but they all had
normal cardiopulmonary and renal function. Bone
marrow was collected from the posterior iliac crests
at least 4-weeks after any chemotherapy,
cryopreserved and stored in liquid nitrogen
(Gilmore, 1983). Mitomycin C was given as a single
dose of 40-50mgm L2 Iv. infusion was over 45min
through a central venous line. Hepatic arterial
infusion was via a catheter placed percutaneously
into the femoral artery and introduced into the
hepatic artery. Mitomycin C was diluted 1 mg to
10ml of normal saline and infused under pressure
(using a pressure bag), 45-60min. Patients were
nursed in single rooms and given non-absorbable
antibiotics and cotrimoxazole. They were nursed in
reverse barrier isolation whilst they were
neutropenic (neutrophils <1.0 x 1091-1). Platelet
infusions were given as required. The infused bone
marrow was stored between 1-7 months prior to
infusion. It was rapidly thawed and infused 48
hours after the Mitomycin C. An average of
1.2 x 108 nucleated cellskg-1 and 8700 CFU-
GM kg-I body wt was infused.
Complete remission was defined as absence of
detectable disease, partial remission as a reduction
of tumour volume .50%. Patients were assessed
by physical examination, CT Scanning, Ultra
Sonography and Bone Scintiscan. One patient with
breast cancer had a complete remission (duration:
34+ weeks), the other patient with breast cancer
and the patient with rectal cancer had partial
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responses which both lasted 6 weeks. The fourth
patient had no objective response. Both the breast
cancer patients had responses in liver and in bone,
with complete resolution of bone metastases in one
and temporary resolution of intractable
hypercalcaemia in the other. Myelosuppression was
marked with granulocytes <0.5 x l09l1- and
platelets <20x 1091-1. Haematological recovery
was rapid in 3/4 patients; median time to recovery
of granulocytes (2.0 x 1091-1) was 17 days from the
day the HDMMC was given and platelets
(100 x1091-1) was 16 days. The slowest recovery
was in the patient who received IV HDMMC and
was the most heavily pretreated. The most rapid
recovery was in the third patient who was
previously untreated and was given 50mgm-2 of
Mitomycin C intra-arterially. Non-haematological
toxicity included alopecia and mild diarrhoea in all
patients, severe and prolonged vomiting in two and
acute duodenal ulceration in one which responded
slowly to therapy with i.v. cimetidine. This
ulceration may have been caused by reflux of
Mitomycin C from the hepatic into the
gastroduodenal artery. There was no evidence of
any other significant toxicity, in particular there
was no hepatotoxicity and the liver function tests
remained stable or improved. One patient had an
hepatic arteriogram 6 weeks after therapy which
showed no radiological evidence of vessel damage.
None of the patients became infected.
It would appear feasible to be able to give high
dose Mitomycin C (50mgm-2) safely as a single
hepatic arterial infusion followed by autologous
bone marrow transplantation to accelerate
haematological recovery to relatively young patients
with normal cardiopulmonary and renal function
who have metastatic liver cancer. We have not
studied the pharmokinetics of intra-arterial infusion
of Mitomycin C and so it is uncertain as to
whether there is a definite advantage for drug
delivery to the tumour by this route. However,
there was a high response rate in this small group
of patients with resistant tumours and it seems
likely that a high concentration of Mitomycin C
would have been delivered to the tumour. The
duration of this high concentration might be
prolonged by inflating a balloon catheter for a
short period of time in the inferior vena cava
proximal to the hepatic venous drainage delaying
perfusion of the drug. However, arterial reflux may
prove a problem with this technique. We feel that
i.v. and hepatic intra-arterial infusion of high dose
Mitomycin C with autologous bone marrow rescue
merits further study to ascertain whether there is
increased hepatic uptake of Mitomycin C by the
intra-arterial route, whether this confers a
therapeutic advantage over the intravenous route,
and to further evaluate the role of autologous bone
marrow transplant in this setting and to further
evaluate high dose Mitomycin C as treatment of
cancer metastatic to the liver.
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